Related Experiment Video
Updated: May 1, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
The HSP70 modulator MAL3-101 inhibits Merkel cell carcinoma
Christian Adam1, Anne Baeurle1, Jeffrey L Brodsky2
1Department of Dermatology, University Hospital of Würzburg, Würzburg, Germany.
Abstract:
Merkel Cell Carcinoma (MCC) is a rare and highly aggressive neuroendocrine skin cancer for which no effective treatment is available. MCC represents a human cancer with the best experimental evidence for a causal role of a polyoma virus. Large T antigens (LTA) encoded by polyoma viruses are oncoproteins, which are thought to require support of cellular heat shock protein 70 (HSP70) to exert their transforming activity. Here we evaluated the capability of MAL3-101, a synthetic HSP70 inhibitor, to limit proliferation and survival of various MCC cell lines. Remarkably, MAL3-101 treatment resulted in considerable apoptosis in 5 out of 7 MCC cell lines. While this effect was not associated with the viral status of the MCC cells, quantitative mRNA expression analysis of the known HSP70 isoforms revealed a significant correlation between MAL3-101 sensitivity and HSC70 expression, the most prominent isoform in all cell lines. Moreover, MAL3-101 also exhibited in vivo antitumor activity in an MCC xenograft model suggesting that this substance or related compounds are potential therapeutics for the treatment of MCC in the future.
Insights
A novel HSP70 inhibitor, MAL3-101, effectively induced apoptosis in Merkel Cell Carcinoma (MCC) cell lines. This finding suggests MAL3-101 as a potential therapeutic agent for this aggressive skin cancer.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with limited treatment options.
- Polyoma viruses are implicated in MCC pathogenesis, with viral oncoproteins (Large T antigens) potentially relying on heat shock protein 70 (HSP70).
Purpose of the Study:
- To evaluate the efficacy of MAL3-101, a synthetic HSP70 inhibitor, against MCC cell proliferation and survival.
- To investigate the correlation between HSP70 isoform expression and sensitivity to MAL3-101 in MCC cells.
Main Methods:
- Treatment of multiple MCC cell lines with MAL3-101.
- Assessment of apoptosis induction and cell viability.
- Quantitative mRNA expression analysis of HSP70 isoforms.
- Evaluation of in vivo antitumor activity in an MCC xenograft model.
Main Results:
- MAL3-101 induced significant apoptosis in 5 out of 7 MCC cell lines.
- Sensitivity to MAL3-101 correlated with the expression of the HSC70 isoform, irrespective of viral status.
- MAL3-101 demonstrated in vivo antitumor activity in an MCC xenograft model.
Conclusions:
- MAL3-101 shows promise as a therapeutic agent for Merkel Cell Carcinoma.
- Targeting HSP70, particularly the HSC70 isoform, may be a viable strategy for MCC treatment.
- Further investigation of MAL3-101 and related compounds for MCC therapy is warranted.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
02:23Abnormal Proliferation
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity